Evidence map›Paper›PMID 42859189›Full record

ArticleOncogene2026

Adrenomedullin 2 drives intratumoral cancer cell invasion, intravasation and metastasis.

Konstantin Stoletov, Seyedeh Sara Karimian, Douglas Brown, Alice Amitrano, Bishwa Ranjan Si, Varinder Madhav Verma, Somnath Gupta, Amirali B Bukhari, Suellen Lamb, Konstantinos Konstantopoulos and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Konstantin StoletovDepartment of Oncology, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
Seyedeh Sara KarimianDepartment of Oncology, University of Alberta, Edmonton, AB, T6G 2E1, Canada.ORCID http://orcid.org/0000-0002-7424-2980
Douglas BrownDepartment of Oncology, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
Alice AmitranoDepartment of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID http://orcid.org/0000-0001-7919-2225
Bishwa Ranjan SiDepartment of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD, 21218, USA.
Varinder Madhav VermaDepartment of Biological Sciences, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
Somnath GuptaDepartment of Oncology, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
Amirali B BukhariDepartment of Oncology, University of Alberta, Edmonton, AB, T6G 2E1, Canada.ORCID http://orcid.org/0000-0003-0543-1339
Suellen LambDepartment of Oncology, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
Konstantinos KonstantopoulosDepartment of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID http://orcid.org/0000-0003-2623-1459
Gane Ka-Shu WongDepartment of Biological Sciences, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
John D LewisDepartment of Oncology, University of Alberta, Edmonton, AB, T6G 2E1, Canada. jdlewis@ualberta.ca.ORCID http://orcid.org/0000-0002-7734-1204

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cell intravasation requires both directed invasion toward the vasculature and access to functional blood vessels that act as intravasation sites. Using intravital video microscopy, we identified the peptide hormone adrenomedullin 2 (ADM2) as a critical regulator of this process. ADM2 was selectively upregulated in a highly invasive subpopulation of cancer cells that localize near blood vessels and actively drive intravasation. Knockdown of ADM2 significantly impaired intratumoral cancer cell invasion and intravasation in a chicken embryo metastasis model and in vitro. ADM2-deficient tumors exhibited reduced vascularization, limiting the availability of competent intravasation sites. Moreover, loss of ADM2 suppressed the formation of invasive metastatic lesions, indicating a requirement for ADM2 at multiple stages of the metastatic cascade. Consistently, targeting ADM2 in a mouse metastasis model inhibited the development of large intratumoral blood vessels and reduced metastasis. Collectively, these findings establish ADM2 as a previously unrecognized regulator of tumor-vascular interactions and highlight its potential as a therapeutic target to simultaneously disrupt invasion, vascular support, and metastatic dissemination.

Identifiers

PMID42859189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.